CBIS applauds U.S. government approval of PTSD medical cannabis study
Cannabis Science, Inc. (NASDAQ OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds federal government approval of a University of Arizona study of efficacy of medical cannabis in treating post-traumatic stress disorder (PTSD). Cannabis Science sees this approval by the U.S. Department of Health and Human Services as a watershed moment for federal authorization of medical cannabis research.
"As a premier medical cannabis pharmaceutical company, we welcome the federal government support of a significant patient study of the effectiveness of treating PTSD with medical cannabis. While admittedly a first step, it is a substantial one that moves federal policy in the direction of permitting important patient-based research that we at CBIS believe will show the clear medical value of cannabis for many diseases and conditions," said Dorothy H. Bray, Ph.D., Director & CEO of Cannabis Science, Inc.
For more information about the approved study, please see the following links:
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
SOURCE Cannabis Science, Inc.